Monica Verrico1, Luigi Rossi2, Silverio Tomao3,4, Maria Colonna5, Patrizia Vici6, Federica Tomao7. 1. Oncology Unit, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Aprilia, Italy. 2. Oncology Unit, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Aprilia, Italy, dr.rossi@ymail.com. 3. Division of Medical Oncology A, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. 4. Consorzio Interuniversitario per la Bio-Oncologia (CINBO), Chieti, Italy. 5. Oncology Unit, A. Fiorini Hospital, Terracina, Italy. 6. Medical Oncology, National Cancer Institute, Rome, Italy. 7. Dipartimento Materno Infantile e Scienze Urologiche, Policlinico Umberto I, Sapienza Università di Roma, Rome, Italy.
Abstract
INTRODUCTION: Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies with various clinical presentations and growth rates. NET incidence has been estimated to 2.5-5 per 100,000 people per year, and NET prevalence is 35 per 100,000. They are frequently associated with synchronous or metachronous second primary malignancies (SPM). METHODS: We retrospectively reviewed our institutional database on NET patients. We report on 30 patients with NETs and SPMs from a series of 262 patients with NETs: 10 patients with synchronous NETs (33.3%) and 20 with metachronous SPMs (66.6%). RESULTS: The median patient age was 67 years. Of the 10 synchronous lesions, 50% were observed in the GI tract. The most common locations of these lesions were the colon (15%) and pancreas (25%). In 2 patients, there was an association of prostate neoplasia with a subsequent NET of the pancreas. CONCLUSIONS: Only few studies have examined the association between NETs and SPMs. Our study showed that the risk of second cancer following NETs is increased. In this single-institution retrospective review, our incidence of additional malignancies in patients with NET was 11.4%.
INTRODUCTION:Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies with various clinical presentations and growth rates. NET incidence has been estimated to 2.5-5 per 100,000 people per year, and NET prevalence is 35 per 100,000. They are frequently associated with synchronous or metachronous second primary malignancies (SPM). METHODS: We retrospectively reviewed our institutional database on NET patients. We report on 30 patients with NETs and SPMs from a series of 262 patients with NETs: 10 patients with synchronous NETs (33.3%) and 20 with metachronous SPMs (66.6%). RESULTS: The median patient age was 67 years. Of the 10 synchronous lesions, 50% were observed in the GI tract. The most common locations of these lesions were the colon (15%) and pancreas (25%). In 2 patients, there was an association of prostate neoplasia with a subsequent NET of the pancreas. CONCLUSIONS: Only few studies have examined the association between NETs and SPMs. Our study showed that the risk of second cancer following NETs is increased. In this single-institution retrospective review, our incidence of additional malignancies in patients with NET was 11.4%.
Authors: Luca Giraldi; Alessia Vecchioni; Stefania Boccia; Guido Rindi; Greta Carioli; Mirna Bilotta; Stefano La Rosa; Andrea Imperatori; Marco Volante; Maria Pia Brizzi; Frediano Inzani; Gianluigi Petrone; Giovanni Schinzari; Antonio Bianchi; Stefano Margaritora; Sergio Alfieri; Carlo La Vecchia Journal: Endocrine Date: 2020-08-31 Impact factor: 3.633